Veliparib

Generic Name: Veliparib

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Clinical Trials

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: veliparib (ABT-888)
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2012-06-13

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 12

Registration Number: NCT01617928

Locations: 🇯🇵
Site Reference ID/Investigator# 68622, Tokyo, Japan

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

Phase 1

Completed

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: veliparib
Drug: capecitabine
Radiation: radiation

First Posted Date: 2012-05-02

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 32

Registration Number: NCT01589419

Locations: 🇺🇸
Site Reference ID/Investigator# 99095, Scottsdale, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 68045, Durham, North Carolina, United States
🇦🇺
Site Reference ID/Investigator# 67882, East Melbourne, Australia

and more 3 locations

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Locally Advanced Pancreatic Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Gemcitabine
Drug: Gemcitabine Hydrochloride
Procedure: Magnetic Resonance Imaging
Drug: Veliparib

First Posted Date: 2012-04-26

Last Posted Date: 2025-03-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 88

Registration Number: NCT01585805

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 9 locations

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Carcinoma
Castration-Resistant Prostate Carcinoma
Stage IV Prostate Cancer AJCC v7

Interventions: Drug: Abiraterone Acetate
Other: Laboratory Biomarker Analysis
Drug: Prednisone
Drug: Veliparib

First Posted Date: 2012-04-12

Last Posted Date: 2020-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 159

Registration Number: NCT01576172

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
City of Hope South Pasadena, South Pasadena, California, United States
🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

and more 11 locations

A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small -Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Veliparib
Drug: placebo
Drug: paclitaxel

First Posted Date: 2012-03-22

Last Posted Date: 2015-10-21

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 160

Registration Number: NCT01560104

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: BRCA2 Mutation Carrier
Recurrent Fallopian Tube Carcinoma
Ovarian Epithelial Tumor
Recurrent Ovarian Carcinoma
BRCA1 Mutation Carrier
Recurrent Primary Peritoneal Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Veliparib

First Posted Date: 2012-02-29

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT01540565

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
The Hospital of Central Connecticut, New Britain, Connecticut, United States

and more 150 locations

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Phase 1

Completed

Conditions: Fibrillary Astrocytoma
Untreated Childhood Anaplastic Astrocytoma
Anaplastic Astrocytoma
Giant Cell Glioblastoma
Glioblastoma
Gliosarcoma
Untreated Childhood Fibrillary Astrocytoma
Untreated Childhood Gliosarcoma
Childhood Mixed Glioma
Untreated Childhood Brain Stem Glioma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temozolomide
Drug: Veliparib

First Posted Date: 2012-01-23

Last Posted Date: 2019-08-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT01514201

Locations: 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 9 locations

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Placebo
Drug: Veliparib
Drug: Carboplatin
Drug: Temozolomide
Drug: Paclitaxel

First Posted Date: 2012-01-10

Last Posted Date: 2021-10-25

Lead Sponsor: AbbVie

Target Recruit Count: 294

Registration Number: NCT01506609

Locations: 🇨🇦
Sunnybrook Health Sciences Ctr /ID# 77373, Toronto, Ontario, Canada
🇺🇸
The Angeles Clinic and Researc /ID# 60743, Los Angeles, California, United States
🇺🇸
University of Pennsylvania /ID# 60753, Philadelphia, Pennsylvania, United States

and more 117 locations

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Veliparib
Radiation: Standard radiation treatment

First Posted Date: 2011-11-22

Last Posted Date: 2017-12-15

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 33

Registration Number: NCT01477489

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Phase 1

Completed

Conditions: Recurrent, Epithelial Ovarian Cancer

Interventions: Drug: Veliparib

First Posted Date: 2011-11-16

Last Posted Date: 2016-11-16

Lead Sponsor: Vejle Hospital

Target Recruit Count: 49

Registration Number: NCT01472783

Locations: 🇩🇰
Department of Oncology, Vejle Hospital, Vejle, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy